Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328394 | 1.00 | GAA (0.52) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL9840066 | 0.82 | CHRNB2 (0.59) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL9840069 | 0.82 | CHRNB2 (0.59) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15286402 | 0.80 | LMNA (0.50) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15299573 | 0.80 | LMNA (0.50) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15286403 | 0.80 | LMNA (0.50) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL7503011 | 0.77 | GAA (0.57) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15299572 | 0.77 | GAA (0.48) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15286400 | 0.77 | KMT2A (0.45) | GAAMAPTLMNAL3MBTL1KMT2A | |
| SCHEMBL15224479 | 0.77 | GAA (0.48) | GAAMAPTLMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| US-6900202-B2 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | CHRNA2, CHRNA7, CHRNB2 | GAA 4187/4885MAPT 2454/4885LMNA 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.